Found vs Sequence 2026: GLP-1 Weight Loss Programs Compared

Found vs Sequence vs Trimi: Full Comparison Table

Pricing Breakdown: What You Actually Pay

Pricing is where the Found versus Sequence difference becomes most concrete. Found positions itself as the accessible mid-tier option, with semaglutide plans starting at $129 per month and tirzepatide starting at $199 per month. However, Found uses dose-dependent pricing — meaning your monthly cost increases as your provider titrates you to higher therapeutic doses. A patient who starts at $129 per month may find themselves paying $199 per month within a few months as their dose increases toward the clinically effective range.

Sequence charges a premium from the start: $249 to $399 per month for semaglutide and $349 to $399 per month for tirzepatide. The higher price reflects their dedicated physician team model, where patients work with the same clinical team rather than rotating providers. Sequence frames this as continuity-of-care, which does have clinical value — providers who know your history can make better dose adjustment decisions and catch patterns that new providers might miss.

The critical point is that both platforms prescribe the same compounded medications. The semaglutide molecule does not change based on which platform prescribed it. Trimi offers the same compounded semaglutide at $99 per month and tirzepatide at $125 per month — flat pricing that does not increase with dose escalation, and no contract locking you in if you need to pause or stop treatment. Over a typical 12-month treatment course, the cost differences are significant: Found semaglutide totals $1,548 to $2,388, Sequence semaglutide totals $2,988 to $4,788, and Trimi semaglutide totals $1,188.

Medications: Same Active Ingredients, Different Prices

Both Found and Sequence prescribe compounded semaglutide and tirzepatide — the two GLP-1 receptor agonists with the strongest clinical evidence for weight loss. The active pharmaceutical ingredients are identical across all three platforms in this comparison. What differs is the dispensing pharmacy, the pricing model, and the ancillary services bundled with the prescription.

Semaglutide, the active ingredient in branded Wegovy, works by mimicking the GLP-1 hormone to reduce appetite, slow gastric emptying, and improve satiety signaling. The landmark STEP 1 trial demonstrated 14.9 percent mean body weight loss over 68 weeks in adults with obesity (Wilding et al., New England Journal of Medicine, 2021). These results were achieved with semaglutide 2.4 mg weekly — the same dose range that both Found and Sequence titrate patients toward.

Tirzepatide, the active ingredient in branded Zepbound, is a dual GIP/GLP-1 receptor agonist that targets two incretin pathways simultaneously. The SURMOUNT-1 trial demonstrated up to 22.5 percent mean body weight loss at the highest dose over 72 weeks (Jastreboff et al., New England Journal of Medicine, 2022). Tirzepatide is the more potent of the two medications and is available through both Found and Sequence, though at higher price points than semaglutide. Trimi offers compounded tirzepatide at $125 per month — significantly less than Found's $199 to $299 or Sequence's $349 to $399.

All three platforms source compounded medications from FDA-registered 503B outsourcing pharmacies. The compounding process uses the same active ingredient at the same concentrations, with the same sterility and purity standards. There is no clinical advantage to receiving semaglutide from one platform over another — the pharmacology is identical.

Found: Mid-Range Pricing With Behavioral Coaching

Found differentiates itself through behavioral coaching that runs alongside GLP-1 medication. Their app includes habit-tracking tools, meal guidance, community forums, and access to coaching teams who help patients work through the behavioral and emotional dimensions of weight loss. This is a genuine value-add for patients who struggle with emotional eating, inconsistent habits, or lack of accountability.

The limitation of Found's coaching model is that not every patient uses it. Industry data consistently shows that engagement with digital health tools drops significantly after the first 60 to 90 days. If you stop using Found's coaching features but continue paying $129 to $199 per month for medication alone, you are effectively paying a premium for services you are not consuming. Found's side effect management is handled through their provider team, which is competent but may involve different providers across visits rather than a single dedicated clinician.

Sequence: Premium Pricing With Dedicated Physician Teams

Sequence charges a premium because their model centers on dedicated physician teams rather than rotating providers. When you join Sequence, you are assigned to a clinical team that manages your treatment from intake through maintenance. This continuity means your physician knows your history, understands your response patterns, and can make nuanced dosing decisions based on longitudinal data rather than a single visit snapshot.

The trade-off is cost. At $249 to $399 per month for semaglutide, Sequence is the most expensive option in this comparison — two to four times the cost of Trimi for the same active medication. The clinical model is legitimately stronger than most telehealth competitors, but the question every patient must answer is whether that additional clinical depth is worth $150 to $300 per month more than what a focused, affordable provider charges. Sequence's side effect management benefits from the dedicated team model, where providers can track patterns across visits and adjust proactively.

Coaching and Support: Different Models, Different Values

The Found versus Sequence coaching comparison reveals fundamentally different philosophies. Found invests in behavioral tools — the app, the habit tracker, the community features, the coaching team. Their approach says: weight loss requires behavior change alongside medication, and technology can deliver that behavior change at scale. Sequence invests in clinical depth — the dedicated physician, the continuity of care, the sophisticated dose management. Their approach says: the medication is the primary intervention, and the physician relationship is what optimizes it.

Both philosophies have merit. Research supports that behavioral interventions improve weight loss outcomes when combined with pharmacotherapy (Wadden et al., NEJM, 2024). Patients who receive structured behavioral support alongside GLP-1 medication tend to lose modestly more weight and maintain it longer than those receiving medication alone. However, the incremental benefit of structured coaching varies widely between individuals. Self-motivated patients with existing healthy habits may see minimal additional benefit from coaching, while patients struggling with emotional eating or poor food relationships may find it transformative.

Neither Found nor Sequence offers the combination of clinical focus and cost efficiency that characterizes Trimi's model. Trimi provides licensed provider oversight, dose management, and side effect support at $99 per month for semaglutide — allowing patients to invest the $30 to $300 per month savings into independent coaching, nutrition counseling, gym memberships, or healthier food choices if they want behavioral support beyond what their provider offers.

Where Both Found and Sequence Fall Short

Clinical Evidence: What the Trials Actually Show

When evaluating Found versus Sequence, it is essential to ground the comparison in clinical evidence rather than marketing claims. The weight loss results patients achieve are primarily driven by the medication, not the platform. Both prescribe the same active ingredients studied in the same landmark trials.

The STEP 1 trial enrolled 1,961 adults with BMI of 30 or greater (or 27 or greater with at least one weight-related comorbidity) and randomized them to semaglutide 2.4 mg weekly or placebo. At 68 weeks, the semaglutide group achieved a mean body weight reduction of 14.9 percent compared to 2.4 percent for placebo (Wilding et al., New England Journal of Medicine, 2021). Approximately one-third of participants lost 20 percent or more of their body weight. These are the results patients on either Found or Sequence can reasonably expect with adherent semaglutide use.

The SURMOUNT-1 trial evaluated tirzepatide across three dose levels (5 mg, 10 mg, and 15 mg) in 2,539 adults with obesity. At 72 weeks, mean body weight reductions were 15.0 percent (5 mg), 19.5 percent (10 mg), and 20.9 percent (15 mg), with the highest responders achieving up to 22.5 percent body weight loss (Jastreboff et al., New England Journal of Medicine, 2022). These tirzepatide results are particularly relevant for patients considering Found's $199 to $299 per month or Sequence's $349 to $399 per month tirzepatide programs — or Trimi's $125 per month alternative.

Neither Found nor Sequence has published independent clinical outcomes data demonstrating that their specific platform produces superior results to other providers prescribing the same medications. The clinical trials were conducted with the medication, not with any specific telehealth platform's coaching model. Any provider that correctly prescribes, titrates, and monitors GLP-1 therapy should produce results consistent with the published trial data.

Why Trimi Offers Better Value Than Both

For patients who have compared Found and Sequence and want the same medication at a lower price, Trimi provides a direct alternative. The medication is identical — compounded semaglutide and tirzepatide from FDA-registered pharmacies. The clinical oversight is provider-guided with dose management and side effect support. What is different is the price and the commitment structure.

The Bottom Line: Found vs Sequence vs Trimi

Found is the right choice for patients who want behavioral coaching tools bundled with their GLP-1 prescription at a moderate price point. If app-based habit tracking, meal guidance, and community support are features you will actively use throughout your treatment, Found's $129 to $199 per month semaglutide pricing represents reasonable value for the combined offering. Review our full Found review for a deeper analysis.

Sequence is the right choice for patients with complex metabolic conditions who need dedicated physician oversight and are willing to pay a premium for continuity-of-care. If you have multiple comorbidities, a complicated medication history, or previous treatment failures that require nuanced clinical management, Sequence's $249 to $399 per month dedicated team model may justify the higher cost. Read our full Sequence review for more details.

For the majority of patients — those who want effective GLP-1 medication, competent clinical oversight, and a price that makes long-term treatment sustainable — Trimi at $99 per month offers the strongest value proposition. The medication is identical, the provider support is included, there are no contracts, and the annual savings of $360 to $3,600 compared to Found and Sequence are better directed toward your overall health and wellbeing. Explore the cheapest GLP-1 options in 2026 for additional cost comparisons across the market.